The world is talking about ending AIDS. AVAC’s advocacy is dedicated to realizing that vision. To get there we must:
With HIV Vaccine Awareness Day (HVAD) in the spotlight earlier this month, AVAC’s May episode of Px Pulse features four experts steeped in HIV vaccine research. Together they help set expectations for where the field is now and where it is going.
HIV Vaccine Awareness Day, May 18, commemorates the vital and ongoing work to develop a vaccine against HIV. This work advances because of the ingenuity, courage and commitment of trial participants, host communities, funders, scientists and advocates. AVAC salutes the collective trust and sustained dedication to end the epidemic.
Research on broadly neutralizing antibodies (bNAbs) is taking the field of HIV prevention science in new directions, with implications for new prevention interventions and vaccine development. There’s much to know and much to learn about these powerful instruments of the immune system.
In the new issue of Px Wire, AVAC gives our take on this year’s PEPFAR process for establishing the Country Operational Plans (COPs). These plans define what work will be done with PEPFAR money at the country level and how that work will be evaluated in each of the 63 countries that receive PEPFAR money.
AVAC has an extensive online resource library with hundreds of Reports, Publications, Infographics & more. And it includes powerful search features to find exactly what you’re looking for.
AVAC uses education, policy analysis, advocacy, community mobilization and a network of global collaborations to accelerate ethical development and global delivery of biomedical HIV prevention options. Read more
AVAC advocates for a comprehensive response to the epidemic, involving smart use of every proven HIV prevention option available today and sustained research into many new strategies.